Early mortality in multiple myeloma (Q45412209)

14 December 2017

title

Early mortality in multiple myeloma (English)

1 reference

14 December 2017

W I Gonsalves

1 reference

14 December 2017

L J Costa

1 reference

14 December 2017

S K Kumar

series ordinal

1 reference

14 December 2017

publication date

12 February 2015

1 reference

14 December 2017

1 reference

14 December 2017

1 reference

14 December 2017

1 reference

14 December 2017

page(s)

1616-1618

1 reference

Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study

14 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.33

Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.33

Recent major improvement in long-term survival of younger patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.33

Improved survival among younger but not among older patients with Multiple Myeloma in the Netherlands, a population-based study since 1989.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.33

Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.33

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.33

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.33

First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.33

Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.33

Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.33

Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.33

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.33

Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.33

Improved long-term survival in multiple myeloma up to the age of 80 years

21 January 2018

1 reference

12 December 2020

Participation in cancer clinical trials: race-, sex-, and age-based disparities

1 reference

12 December 2020

Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma

1 reference

12 December 2020

Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple m

1 reference

12 December 2020

Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study

1 reference

12 December 2020

Identifiers

DOI

10.1038/LEU.2015.33

1 reference

Dimensions Publication ID

14 December 2017

1032272531

0 references

Fatcat ID

release_xg2aqhaazfgbldf7yqh7mi6c2e

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/xg2aqhaazfgbldf7yqh7mi6c2e

24 November 2022

mapped directly with Wikidata item

1 reference